SCHEMBL7577466

SCHEMBL7577466

c1cncc(CCNc2nccc(-n3cnc4ccccc43)n2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 17/20 1.00
MKNK2 Q9HBH9 15/20 1.00
LCK P06239 1/20 0.68
OGA O60502 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7025681 0.90 MKNK1 (0.87) MKNK1MKNK2LCK
SCHEMBL18803526 0.88 MKNK1 (1.00) MKNK1MKNK2LCK
SCHEMBL7512099 0.86 MKNK1 (0.76) MKNK1MKNK2LCK
SCHEMBL7502751 0.86 MKNK1 (0.87) MKNK1MKNK2LCK
SCHEMBL18803653 0.85 MKNK2 (0.78) MKNK1MKNK2LCK
SCHEMBL7501680 0.83 MKNK2 (0.71) MKNK1MKNK2LCKOGA
SCHEMBL7505860 0.83 MKNK1 (0.72) MKNK1MKNK2LCK
SCHEMBL18803599 0.83 MKNK2 (1.00) MKNK1MKNK2
SCHEMBL7022617 0.81 LCK (1.00) MKNK1MKNK2LCK
SCHEMBL21554171 0.81 MKNK1 (1.00) MKNK1MKNK2LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851082-B2 Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2) NORTHWESTERN UNIVERSITY (US) 2020-12-01 US disclosed
US-20170121326-A1 SUBSTITUTED AROMATIC N-HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE INTERACTING KINASE 1 (MNK1) AND 2 (MNK2) NORTHWESTERN UNIVERSITY (US) 2017-05-04 US disclosed
US-20170121326-A1 SUBSTITUTED AROMATIC N-HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE INTERACTING KINASE 1 (MNK1) AND 2 (MNK2) NORTHWESTERN UNIVERSITY (US) 2017-05-04 US disclosed
EP-1206265-A4 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2002-08-07 EP disclosed
EP-1206265-A1 SRC KINASE INHIBITOR COMPOUNDS Merck & Co., Inc. (US) 2002-05-22 EP disclosed
WO-2001000213-A1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO., INC. (US) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10851082-B2 Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2) MAP4K2, MAP3K20, MKNK2 MKNK1 5/4885MKNK2 3/4885LCK 203/4885
US-20170121326-A1 SUBSTITUTED AROMATIC N-HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE INTERACTING KINASE 1 (MNK1) AND 2 (MNK2) MAP4K2, MAP3K20, MKNK2 MKNK1 5/4885MKNK2 3/4885LCK 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.